Drugging the Master Regulator TP53 in Cancer: Mission Possible?

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). February 18, 2021 ARTICLE CITATION DOI: 10.1200/JCO.21.00192 Journal of Clinical Oncology - published online before print April 2, 2021 PMID: 33797953 Drugging the Master Regulator TP53 in Cancer: Mission Possible? Giovanni Blandino , MD1xGiovanni BlandinoSearch for articles by this author Show More 1Oncogenomic and Epigenetic Unit, Department of Research, Advanced Diagnostic and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy https://doi.org/10.1200/JCO.21.00192 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologySUPPORTSupported by the Italian Association for Cancer Research (AIRC).AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTDrugging the Master Regulator TP53 in Cancer: Mission Possible?The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).No potential conflicts of interest were reported. Companion Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)